Encorafenib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ENCORAFENIB |
|---|---|
| Type | Drug |
| Aliases | BraftoviЕнкорафеніб |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-CRC DIS-MELANOMA |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Drug Facts
| Class | BRAF inhibitor (oral, V600-selective) |
|---|---|
| Mechanism | Selective ATP-competitive BRAF V600E/K kinase inhibitor. Longer target-residence time vs vemurafenib/dabrafenib → less paradoxical ERK activation in WT BRAF cells. In mCRC BRAF V600E + cetuximab (BEACON CRC) — first BRAF-targeted approval in CRC. |
| Typical dosing | CRC BRAF V600E (BEACON): 300 mg PO daily (with cetuximab 400→250 mg/m² weekly). Melanoma (with binimetinib): 450 mg PO daily. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
BEACON CRC (Kopetz NEJM 2019, Lancet 2022 update): encorafenib + cetuximab vs irinotecan/FOLFIRI + cetuximab control — mOS 9.3 vs 5.9 mo in BRAF V600E mCRC 2L+. Triplet arm (enco + cetux + binimetinib) showed numerically higher ORR but no OS benefit vs doublet — doublet is the current standard. COLUMBUS (melanoma): encorafenib + binimetinib vs vemurafenib mPFS 14.9 vs 7.3 mo. Skin surveillance for new cutaneous SCC and primary melanoma mandatory throughout treatment (BRAFi class effect — derm exam q3 mo). Baseline + serial ECG (QTc), LFTs, derm + ophthalmologic exam. UA: registered for melanoma + CRC indications; НСЗУ does not reimburse — out-of-pocket. Dabrafenib+trametinib remains the reimbursed BRAFi+MEKi combo in UA melanoma practice.
Used By
Regimens
REG-ENCORAFENIB-BINIMETINIB-MELANOMA- Encorafenib + binimetinib (BRAF V600E/K melanoma)REG-ENCORAFENIB-CETUXIMAB- Encorafenib + Cetuximab (BEACON CRC)